NASDAQ:AKRX - Akorn Stock Price, Forecast & News

Akorn trades on the NASDAQ under the ticker symbol "AKRX."

Akorn, Inc. (NASDAQ:AKRX) announced its quarterly earnings data on Thursday, October, 31st. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.06. The firm had revenue of $176.24 million for the quarter, compared to analysts' expectations of $176.15 million. Akorn had a negative net margin of 53.62% and a negative return on equity of 19.95%. The business's revenue for the quarter was up 6.4% on a year-over-year basis. During the same period last year, the firm earned ($0.06) earnings per share. View Akorn's Earnings History.

3 equities research analysts have issued 12-month price targets for Akorn's stock. Their forecasts range from $4.00 to $8.00. On average, they anticipate Akorn's stock price to reach $5.67 in the next twelve months. This suggests a possible upside of 316.7% from the stock's current price. View Analyst Price Targets for Akorn.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Akorn.

News stories about AKRX stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Akorn earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Akorn.

Akorn saw a decline in short interest in January. As of January 15th, there was short interest totalling 5,820,000 shares, a decline of 31.6% from the December 31st total of 8,510,000 shares. Based on an average trading volume of 2,360,000 shares, the short-interest ratio is presently 2.5 days. Currently, 6.1% of the company's shares are sold short. View Akorn's Current Options Chain.

Some companies that are related to Akorn include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Akorn investors own include Celgene (CELG), Integrated Device Technology (IDTI), Skechers USA (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC), Quantenna Communications (QTNA), Ulta Beauty (ULTA), Paycom Software (PAYC) and Square (SQ).

Akorn's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (8.38%), State Street Corp (2.67%), Connor Clark & Lunn Investment Management Ltd. (1.03%), Maverick Capital Ltd. (0.98%), Bank of New York Mellon Corp (0.89%) and Marshall Wace LLP (0.78%). Company insiders that own Akorn stock include Alan D Weinstein, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Institutional Ownership Trends for Akorn.

AKRX stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Jacobs Levy Equity Management Inc., Goldman Sachs Group Inc., Spark Investment Management LLC, Assenagon Asset Management S.A., Connor Clark & Lunn Investment Management Ltd., UBS Group AG and Bank of America Corp DE. View Insider Buying and Selling for Akorn.

AKRX stock was purchased by a variety of institutional investors in the last quarter, including Maverick Capital Ltd., Renaissance Technologies LLC, Marshall Wace LLP, Marshall Wace North America L.P., Oxford Asset Management LLP, Gabelli Funds LLC, Dynamic Technology Lab Private Ltd and Great West Life Assurance Co. Can. Company insiders that have bought Akorn stock in the last two years include Alan D Weinstein, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View Insider Buying and Selling for Akorn.

Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AKRX stock can currently be purchased for approximately $1.36.

Akorn has a market capitalization of $171.56 million and generates $694.02 million in revenue each year. The company earns $-401,910,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Akorn employs 2,191 workers across the globe.View Additional Information About Akorn.

The official website for Akorn is http://www.akorn.com/.

Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]